Failure of Isoniazid Chemoprophylaxis during Infl iximab Therapy
To the Editor: A patient with ankylosing spondylitis was treated with infl iximab, a tumor necrosis factor (TNF) blocker that has been associated with reactivation of latent tuberculosis (TB). Because of reactivity in testing with purifi ed protein derivative, isoniazid chemoprophylaxis was started 2 weeks before infl iximab therapy. Four months later, a cavitary lung infection developed in the patient, caused by isoniazid-resistant Mycobacterium kansasii.
To our knowledge, this is the fi rst documented case of failure of isoniazid prophylaxis due to the emergence of isoniazid-resistant mycobacteria in patients receiving infl iximab therapy. TNF blockers have contributed to the control of rheumatic diseases (1) . Many of the damaging infl ammatory mechanisms that they inhibit are important in maintaining TB in the latent phase. Consequently, drugs that target TNF functions have been associated with an increased risk of TB (2) . For these reasons, prophylactic chemotherapy should be offered to patients with latent TB (3) . We show the failure of isoniazid chemoprophylaxis in a patient receiving infl iximab therapy in whom lung infection developed, caused by isoniazid-resistant M. kansasii.
A 39-year-old man with ankylosing spondylitis was admitted to Jimenez Diaz Foundation hospital, Madrid, because of fever and lung infi ltrates. He had been receiving antiinfl ammatory drug therapy without amelioration of his symptoms. Therefore, treatment with infl iximab was considered. Fifteen years before, the patient's father had had pulmonary TB caused by M. tuberculosis that was susceptible to fi rst-line antituberculous drugs, and the patient was given chemoprophylaxis with isoniazid, 300 mg/day, during a 9-month period. Before beginning infl iximab therapy, the patient was again given chemoprophylaxis with isoniazid, 300 mg/day, because a tuberculin test with 5 units of purifi ed protein derivative showed an induration of 18 mm at 72 hours. Results of chest radiographs were normal, and cultures for mycobacteria were negative. Results of HIV testing were also negative.
After 4 months of infl iximab therapy, fever, cough, and sputum production developed. New radiographs showed bilateral upper lung fi eld infi ltrates with cavitary lesions. Three acid-fast stains of sputum were positive, and treatment with rifampin, isoniazid, pyrazinamide, and ethambutol was started.
A heavy growth of photochromogenic mycobacteria was detected in 3 sputum cultures. The isolate was identifi ed as M. kansasii genotype 1 by using common biochemical tests and PCR-restriction fragment length polymorphism analysis of the hsp65 gene (4). Susceptibility tests showed resistance to isoniazid (>5 μg/mL), streptomycin, pyrazinamide, p-amino-salicylic acid, and kanamycin but susceptibility to rifampin, ethambutol, and fl uoroquinolones.
Treatment was continued with a combination of rifampin, levofl oxacin, and ethambutol. Sputum cultures taken after 4, 6, and 9 months of antimicrobial drug therapy were negative. After 20 months of treatment, the patient was doing well with a partial resolution of lung infi ltrates, and new cultures were negative.
Isoniazid chemoprophylaxis can effectively lessen the likelihood of active TB in patients treated with TNF antagonists (5) . However, at least 1 failure of TB chemoprophylaxis in a severely immunocompromised patient treated with infl iximab and methotrexate has been published (6). Our patient is unique because the mycobacterial lung infection seemed to emerge as a result of the lack of activity of iso-
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niazid chemoprophylaxis due to resistance of the infecting organism.
Decreased susceptibility to isoniazid among M. kansasii isolates is common (7, 8) , and this microorganism is naturally resistant to pyrazinamide (9) . This pattern of resistance is a serious obstacle for the use of these drugs in monotherapy or when combined with rifampin in the prevention of lung disease caused by M. kansasii (10) .
The source of the infection in this patient is unknown. In a large series of infectious diseases associated with infl iximab therapy, nontuberculous mycobacteria were isolated in 9% of the patients who had mycobacterial diseases (2) . As in our patient, these infections developed shortly after initiation of treatment with infl iximab, which suggests that reactivation of a latent infection is the most probable origin of the disease. Although a mildly positive tuberculin skin test result can be observed in patients infected with atypical mycobacteria, the strong reaction seen in this patient suggests a latent infection with M. tuberculosis (10) . We could speculate on the possibility of a double infection with M. tuberculosis (contracted through household contacts with his father) and M. kansasii through environmental exposure. In this scenario, isoniazid chemoprophylaxis could have prevented the former but not the latter.
In summary, failure of isoniazid chemoprophylaxis can be anticipated in patients who initiate treatment with infl iximab and who have latent infections due to M. kansasii. Despite routine antituberculous chemoprophylaxis, patients receiving infl iximab therapy should be carefully evaluated for lung infection caused by atypical mycobacteria. To the Editor: India is contributing nearly one third of the world's tuberculosis (TB) cases and has the highest rate of new TB cases (1) . Prevalence of multidrug-resistant TB (MDR TB) cases is on the rise in India, and proportions of new cases of MDR TB have been observed to vary from 1.1% to 5.3% in most of the reported studies. The proportion of previously treated patients with MDR TB varied from 8% to 67% (2) . Although these studies have been conducted in different parts of India, they indicate an increasing trend of MDR TB cases.
MDR TB cases threaten the effectiveness of chemotherapy for both treatment and control of TB and require the use of second-line drugs that are more expensive, toxic, and less effective than fi rst-line anti-TB drugs (3). The Green Light Committee established by the Stop TB partners (4), which ensures the proper use of second-line drugs to prevent increasing drug resistance in MDR TB cases in resource-limited countries, encountered resistance to these drugs. This led to the emergence of new terminology in relation to drug-resistant TB, i.e., extensively drug-resistant TB (XDR TB). XDR TB is defi ned as TB caused by a Mycobacterium tuberculosis strain that is resistant to at least rifampin and isoniazid among the fi rst-line anti-TB drugs (MDR TB) in addition to resistance to any fl uoroquinolones and at least 1 of 3 injectable second-line drugs (5) . A recent report describes the current prevalence of XDR TB worldwide (6) . Although India has high annual risk for TB cases and increasing prevalence of MDR TB cases, XDR TB has not yet been described in India.
From December 2000 through December 2002, 68 MDR TB isolates
